SG Americas Securities LLC Invests $36,000 in Harvard Bioscience, Inc. (NASDAQ:HBIO)

SG Americas Securities LLC bought a new stake in shares of Harvard Bioscience, Inc. (NASDAQ:HBIO) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 13,409 shares of the medical instruments supplier’s stock, valued at approximately $36,000.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Allspring Global Investments Holdings LLC purchased a new position in shares of Harvard Bioscience during the 2nd quarter worth $31,000. Cubist Systematic Strategies LLC bought a new position in Harvard Bioscience in the 2nd quarter worth $40,000. Price T Rowe Associates Inc. MD purchased a new position in Harvard Bioscience during the first quarter valued at $54,000. Hillsdale Investment Management Inc. bought a new stake in Harvard Bioscience during the first quarter valued at about $112,000. Finally, Gabelli Funds LLC purchased a new stake in Harvard Bioscience in the second quarter worth about $128,000. 80.87% of the stock is owned by hedge funds and other institutional investors.

Harvard Bioscience Stock Up 1.2 %

NASDAQ HBIO opened at $2.45 on Wednesday. The stock’s 50-day moving average price is $2.66 and its 200-day moving average price is $3.02. The company has a market capitalization of $106.40 million, a P/E ratio of -12.25 and a beta of 1.29. The company has a quick ratio of 0.94, a current ratio of 2.05 and a debt-to-equity ratio of 0.48. Harvard Bioscience, Inc. has a 52 week low of $2.30 and a 52 week high of $5.56.

Harvard Bioscience (NASDAQ:HBIO) last released its earnings results on Thursday, August 8th. The medical instruments supplier reported ($0.03) EPS for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.06). The firm had revenue of $23.10 million for the quarter, compared to the consensus estimate of $29.91 million. Harvard Bioscience had a negative return on equity of 2.70% and a negative net margin of 10.56%. On average, equities research analysts predict that Harvard Bioscience, Inc. will post 0.11 earnings per share for the current year.

About Harvard Bioscience

Harvard Bioscience, Inc develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings.